|
|
Profile
|
Delegates :
President & CEO, Ei Yamada |
|
Incorporated :
December 17 , 1999 |
Paid in Capital :
5658 Million yen |
Employees :
48 人 |
Address :
4F, Saito Bio-Incubator 7-7-15, Saito-asagi, Ibaraki OSAKA
〒567-0085
|
TEL/FAX :
+81-3-5730-2630 / +81-3-5730-2635 |
URL：
http://www.anges-mg.com/en |
Attachment :
|
Mission/Background :
AnGes MG is a biotech company founded in December 1999 as a spin-out of Osaka University. AnGes MG focuses on the development and commercialisation of gene-based medical products including gene therapy, nucleic acid medical products and therapeutic vaccines for intractable diseases with high unmet medical needs. |
|
Technology & Business
|
AnGes MG is currently conducting 2 major proprietary development projects; HGF (Hepatocyte Growth Factor) Plasmid and NF-kB Decoy Oligonucleotide.
<HGF Plasmid>
HGF Plasmid (Plasmid DNA encoding HGF gene) is designed to provide treatment for diseases such as Peripheral Arterial Disease with its angiogenic function. Japanese Phase 3 study conducted in patients with Critical Limb Ischemia showed favorable efficacy and safety results. HGF Plasmid is currently being developed as treatment for 1) Critical Limb Ischemia and 2) Primary Lymphedema.
<NF-kB Decoy Oligonucleotide>
NF-kB Decoy Oligonucleotide is a specific inhibitor for NF-kB that acts as a switch to a gene cluster involved in the immune inflammatory response in the body. Research and development is performed to develop products for immune and inflammatory diseases.
Itis currently being developed as 1) Atopic Dermatitis ointment drug, 2) drug-coated balloon catheter to prevent restenosis, and 3) disc degeneration treatment.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
HGF Plasmid
|
Phase3
|
Target: Critical Limb Ischemia
|
NDA in Japan under conditional approval system
|
NF-kB Decoy Oligonucleotide
|
Phase3
|
Target: Atopic Dermatitis (moderate to severe atopic skin symptoms on face)
|
NDA in Japan
|
NF-kB Decoy Oligonucleotide
|
Preclinical
|
Target: Disc Degeneration
|
Start P1/2 study in the US
|
|
|
|
|
|
|
|
|
|
Highlights
|
-HGF Plasmid for Critical Limb Ischemia: Physician-led study in Japan
-NF-kB Decoy Oligonucleotide for Atopic Dermatitis: completed follow-up period in Japan Phase 3 study
-Drug-coated balloon catheter with NF-kB Decoy Oligonucleotide: completed follow-up period in the pivotal clinical study in Japan
|
|
Alliance strategy
|
License-out: HGF Plasmid (excluding Critical Limb Ischemia in the US and Japan), NF-kB Decoy Oligonucleotide, and Hypertension DNA Vaccine
|
|
|